The content of hemopoietic precursors in the bone marrow, its morphological composition, structural and functional organization, binding of hemopoietic precursors by adherent cells, and expression of receptors for erythroblasts and sialoadhesin on bone marrow macrophages were studied in CBA/CaLac mice with hypoplasia of hemopoiesis caused by etoposide in a maximum permissible dose. It was found that recovery of hemopoiesis after cytostatic treatment was related to accelerated maturation of hemopoietic precursors and increased ability of microenvironmental cells to bind hemopoietic cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1013021726565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
Ann Hematol
January 2025
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone.
View Article and Find Full Text PDFReduction of HLA antibodies by bi-specific antibody blinatumomab.
Hum Immunol
November 2024
HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States. Electronic address:
Donor specific antibodies against human leukocyte antigen (HLA) can cause engraftment failure in hemopoietic stem cell transplantation, or antibody mediated rejection in solid organ transplantation. To increase the chance of successful transplants, donor specific antibodies have to be reduced or depleted in patients with high levels of HLA antibodies. However, no current therapies have been proven to remove or reduce HLA antibodies effectively in the majority of patients.
View Article and Find Full Text PDFInducible pluripotent stem cells to study human mast cell trajectories.
Mucosal Immunol
October 2024
Mary H Weiser Food Allergy Center, Michigan Medicine, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA; Department of Pathology, Michigan Medicine, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA. Electronic address:
Article Synopsis
- The study explores human mast cell (MC) differentiation from induced pluripotent stem cells (iPSCs), aiming to enhance understanding of MC development and subtypes due to limitations in current cellular models.* -
- Analysis using flow cytometry shows distinct hematopoietic progenitor populations during the differentiation process, with various characteristics identified in early and later stages, including hypergranular and hypogranular cell types.* -
- Single-cell RNA sequencing (scRNA-seq) highlighted diverse cell populations, revealing several progenitor types, and demonstrated that cultured MC precursors can be matured into uniform mature MCs through specific media.*
Late Adverse Effects after Treatment for Childhood Acute Leukemia.
Acta Med Acad
April 2024
Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Royal Victoria Infirmary; Translational and Clinical Research Institute, and Centre for Cancer, Newcastle University, Newcastle upon Tyne, United
The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis.
View Article and Find Full Text PDFIntracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells.
Brain Pathol
January 2025
Institute of Biochemistry and Cell Biology (IBBC), National Research Council of Italy (CNR), c/o International Campus "A. Buzzati-Traverso", Rome, Italy.
Article Synopsis
- Many brain tumors in kids are hard to treat, but new therapies might help them!
- A study with mice showed that a chemical called Cxcl3 can help brain cells move and develop properly, reducing the size of tumors!
- Researchers also found that Cxcl3 works in different types of brain tumors in humans, suggesting it could be a useful treatment option!
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!